LAPTM4B allele *2 is a marker of poor prognosis for gallbladder carcinoma

PLoS One. 2012;7(9):e45290. doi: 10.1371/journal.pone.0045290. Epub 2012 Sep 12.

Abstract

Background: Lysosomal protein transmembrane 4 beta (LAPTM4B) is a novel cancer-related gene which has two alleles designated LAPTM4B*1 and LAPTM4B*2. In this study we investigated the correlation of LAPTM4B genotype with prognosis and clinicopathologic features in patients who had undergone curative resection for gallbladder carcinoma (GBC).

Methodology/principal findings: PCR assay was performed to determine the LAPTM4B genotype in 85 patients. The correlation of LAPTM4B genotype with clinicopathologic parameters was assessed with the Chi-squared test. Differences in patient survival were determined by the Kaplan-Meier method. Multivariate analysis of prognostic factors was carried out with Cox regression analysis. Patients with LAPTM4B *2 had both significantly shorter overall survival (OS) and shorter disease-free survival (DFS) (both P<0.001). Multivariate analysis showed that LAPTM4B genotype is a prognostic factor for OS and DFS (both P<0.001).

Conclusions/significance: LAPTM4B allele *2 is a risk factor associated with poor prognosis in patients with resected GBC, and LAPTM4B status may be therefore be useful preoperatively as an adjunct in evaluation of the operability of GBC.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Alleles
  • Biomarkers, Tumor / genetics*
  • Chi-Square Distribution
  • Female
  • Gallbladder Neoplasms / genetics*
  • Gallbladder Neoplasms / pathology
  • Gallbladder Neoplasms / surgery
  • Genotype
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Membrane Proteins / genetics*
  • Middle Aged
  • Multivariate Analysis
  • Oncogene Proteins / genetics*
  • Polymerase Chain Reaction
  • Prognosis
  • Proportional Hazards Models
  • Risk Assessment / statistics & numerical data
  • Risk Factors

Substances

  • Biomarkers, Tumor
  • LAPTM4B protein, human
  • Membrane Proteins
  • Oncogene Proteins

Grants and funding

This work was supported by grants from the National Nature Science Fund (No. 31000622) and Specialized Research Fund for the Doctoral Program of Higher Education of China (20100001120043). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.